CDK4 and liposarcoma: A panel of sarcoma cells, including SJSA cells, as well as CRL-304328, CRL-304428 and GOT-329 (the latter three derived from well-differentiated liposarcoma and with amplifications of CDK4 and MDM2 genes), were treated with Palbociclib to inhibit CDK4, as well as Nutlin to block the MDM2–p53 interaction.